Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Genetic Immunity Publishes the Technology Roadmap for the Cure of HIV

Abstract:
Genetic Immunity (OTCBB: PWRV), a leader in immunotherapy technology, announced the peer-reviewed publication on the Company's groundbreaking nanotechnology and details on its potential for the cure of HIV. The manuscript is entitled "Nanomedicine applications Towards the Cure of HIV" by J. Lisziewicz and E. R. Toke (www.nanomedjournal.com/article/S1549-9634(12)00287-0/abstract).

Genetic Immunity Publishes the Technology Roadmap for the Cure of HIV

Budapest, Hungary | Posted on October 22nd, 2012

The Scientists of Genetic Immunity pioneered research for the cure of HIV: in 1999 they described in the New England Journal of Medicine the first patients whose immune system was boosted to control HIV after interruption of his daily drug treatment (www.nejm.org/doi/full/10.1056/NEJM199905273402114). This observation inspired development of a new medicine called DermaVir that boosts the immune system to specifically recognize and kill HIV infected cells. Today, DermaVir is the most advanced nanomedicine developed for the cure of HIV.

"We have about 30 potent HIV drugs suppressing viral load, but we do not have any to eliminate the infected cells from the reservoirs. To cure HIV we need new drugs to activate these infected cells and to kill them. In our manuscript we described the new drugs that are needed and the strategy that will result in the cure of HIV. One of these new essential drugs for HIV eradication is DermaVir, our lead HIV-specific immunotherapeutic product. In contrast to the daily oral drugs, DermaVir is administered a few times a year with four patches. Our Clinical Trials have shows DermaVir to be as safe as a placebo and it induced long-lasting HIV-specific T cell production. Our GIEU006 Phase II trial demonstrated significant killing of HIV-infected cells, producing 70% viral load reduction compared to a placebo. Our results suggest that DermaVir provides the immunologic drug component towards the eradication of HIV," said Dr. Julianna Lisziewicz, CEO of Genetic Immunity.

Eradication of HIV is a difficult goal to achieve, because a reservoir of HIV is established soon after infection and it persists even after years of potent antiretroviral treatment. New drugs under development can activate dormant HIV and flush the virus from the reservoirs. However, activation is not enough, HIV-infected cells must be detected and killed by the immune system. In Hepatitis C, which is caused by a virus transmitted through the blood similarly to HIV, the cure rate is up to 75% because the use of drugs that suppress virus replication and induce the immune system to fight the virus. Up to now the cure of HIV has not been achieved with drugs that suppress the virus. Therefore, DermaVir will be required to induce the immune system to fight HIV and contribute to the cure of HIV/AIDS.

Genetic Immunity is a wholly owned subsidiary of Power of the Dream Ventures, Inc. (OTCBB: PWRV).

####

About Power of the Dream Ventures, Inc
Genetic Immunity, a wholly owned subsidiary of Power of the Dream Ventures, Inc. (OTCBB: PWRV), is a clinical stage technology company committed to discovering, developing, manufacturing and commercializing a new class of immunotherapeutic biologic drugs for the treatment of viral infections, cancer and allergy. Our Langerhans cell targeting nanomedicines are exceptional in both safety and immune modulating activity boosting specific Th1-type central memory T cells. These are essential to eliminate infected cells or cancerous cells, and balance the immune reactivity in response to allergens.

In 1988 Drs. Lisziewicz and Lori founded Genetic Immunity in the US after they described the 1st patient whose immune system was boosted to control HIV after treatment interruption (Lisziewicz et al. New England Journal of Medicine 1999) that lead to the invention of DermaVir. The Company's innovative technology team directed by Dr. Lisziewicz, a champion of immune boosting therapies, is now headquartered in Budapest, Hungary. She has been invited into the Scientific Advisory Board of the HIV Cure Initiative led by Francoise Barre-Sinoussi, Nobel Prize Laureate for her HIV research in 2009. For more information please visit www.geneticimmunity.com

For more information, please click here

Contacts:
Dr. Zsolt Lisziewicz
Chief Operating Officer
Genetic Immunity, Inc.
Phone: +36-1-272-0364
Cell: +26-30-211-6402

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Related News Press

News and information

Sandia researchers make solid ground toward better lithium-ion battery interfaces: Reducing the traffic jam in batteries December 13th, 2017

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Columbia engineers create artificial graphene in a nanofabricated semiconductor structure: Researchers are the first to observe the electronic structure of graphene in an engineered semiconductor; finding could lead to progress in advanced optoelectronics and data processing December 13th, 2017

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Possible Futures

Sandia researchers make solid ground toward better lithium-ion battery interfaces: Reducing the traffic jam in batteries December 13th, 2017

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Columbia engineers create artificial graphene in a nanofabricated semiconductor structure: Researchers are the first to observe the electronic structure of graphene in an engineered semiconductor; finding could lead to progress in advanced optoelectronics and data processing December 13th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Nanomedicine

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 December 6th, 2017

Discoveries

Sandia researchers make solid ground toward better lithium-ion battery interfaces: Reducing the traffic jam in batteries December 13th, 2017

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Columbia engineers create artificial graphene in a nanofabricated semiconductor structure: Researchers are the first to observe the electronic structure of graphene in an engineered semiconductor; finding could lead to progress in advanced optoelectronics and data processing December 13th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Announcements

Sandia researchers make solid ground toward better lithium-ion battery interfaces: Reducing the traffic jam in batteries December 13th, 2017

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Columbia engineers create artificial graphene in a nanofabricated semiconductor structure: Researchers are the first to observe the electronic structure of graphene in an engineered semiconductor; finding could lead to progress in advanced optoelectronics and data processing December 13th, 2017

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers

UCLA chemists synthesize narrow ribbons of graphene using only light and heat: Tiny structures could be next-generation solution for smaller electronic devices December 8th, 2017

Device makes power conversion more efficient: New design could dramatically cut energy waste in electric vehicles, data centers, and the power grid December 8th, 2017

Creating a new kind of metallic glass December 7th, 2017

Copper will replace toxic palladium and expensive platinum in the synthesis of medications: The effectiveness of copper nanoparticles as a catalyst has been proven December 5th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project